Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular TargetsCorrado Pelaia, Giorgio Walter Canonica, Girolamo Pelaia et al.|Frontiers in Pharmacology|2022Cited by 157
Molecular Targets for Biological Therapies of Severe AsthmaCorrado Pelaia, Girolamo Pelaia, Caterina Tinello et al.|Frontiers in Immunology|2020Cited by 132
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registryGiorgio Walter Canonica, Massimo Triggiani, Mariangiola Crivellaro et al.|World Allergy Organization Journal|2019Cited by 119
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter StudySanti Nolasco, Nunzio Crimi, Nicola Scichilone et al.|The Journal of Allergy and Clinical Immunology In Practice|2021Cited by 83
Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotypeCorrado Pelaia, Nunzio Crimi, Girolamo Pelaia et al.|Clinical & Experimental Allergy|2020Cited by 77